Advanced search
Publication Cover
Future Science OA Volume 8, 2022 - Issue 3
Submit an article Journal homepage
1,121
Views
2
CrossRef citations to date
0
Altmetric
Research Article

Prediction Scale of Response to Liraglutide Therapy As the Method for Increase of Treatment Efficacy in Type 2 Diabetes

Anna A Mosikian1 Institute of Endocrinology, Laboratory of Diabetology, World-Class Research Centre for Personalized Medicine, Almazov National Medical Research Centre, Saint Petersburg, Russia
,
Tatiana I Golikova1 Institute of Endocrinology, Laboratory of Diabetology, World-Class Research Centre for Personalized Medicine, Almazov National Medical Research Centre, Saint Petersburg, Russia
,
Mariia V Martjanova1 Institute of Endocrinology, Laboratory of Diabetology, World-Class Research Centre for Personalized Medicine, Almazov National Medical Research Centre, Saint Petersburg, RussiaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-1414-0034
ORCID Icon &
Alina Y Babenko1 Institute of Endocrinology, Laboratory of Diabetology, World-Class Research Centre for Personalized Medicine, Almazov National Medical Research Centre, Saint Petersburg, Russia
Article: FSO779 | Received 02 Jun 2021, Accepted 04 Jan 2022, Published online: 31 Jan 2022

References

  • DedovII , ShestakovaMV , GalstyanGR. The prevalence of type 2 diabetes mellitus in the adult population of Russia (NATION study). Diabetes Mellit.19(2), 104–112 (2016).
  • ShestakovaMV , VikulovaOK , ZheleznyakovaAVet al.Diabetes epidemiology in Russia: what has changed over the decade?Ter. Arkh.91(10), 4–13 (2019).
  • GardnerD , ShobekD. In: Basic and Clinical Endocrinology. Chapter 8BINOM Publishing House, Moscow, Russia,464 (2019).
  • LeslieWL , FordI , SattarNet al.The Diabetes Remission Clinical Trial (DiRECT): protocol for a cluster randomised trial. BMC Fam. Pract.17, 20 (2016).
  • PankivVI. Symposium No. 143 Obesity. Int. J. Endocrinol.5(53), 153–156 (2013).
  • BatsisJA , ZbehlikA , BarreLKet al.Impact of obesity on disability, function and physical activity: data from the osteoarthritis initiative. Scand. J. Rheumatol.44(6), 495–502 (2015).
  • TikhonenkoEV , BabenkoAY , ShlyakhtoEV. Predictors of effectiveness of glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes and obesity. Obes. Metab.15(4), 22–30 (2018).
  • DavisJF , SchurdakJD , MagrissoIJet al.Gastric bypass surgery attenuates ethanol consumption in ethanol-preferring rats. Biol. Psychiatry72(5), 354–360 (2012).
  • AlmarshadF. Short-term monotherapy with Liraglutide for weight management: a case study. J. Family Med. Prim. Care8(5), 1804–1806 (2019).
  • OstawalA , MocevicE , KraghNet al.Clinical effectiveness of liraglutide in type 2 diabetes treatment in the real-world setting: a systematic literature review. Diabetes Ther.7(3), 411–438 (2016).
  • EspositoK , MoscaC , BrancarioCet al.GLP-1 receptor agonists and HBA1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials. Curr. Med. Res. Opin.27(8), 1519–1528 (2011).
  • LapollaA , BerraC , MassimoBoemi Met al.Long-term effectiveness of liraglutide for treatment of type 2 diabetes in a real-life setting: a 24-month, multicenter, non-interventional, retrospective study. Adv. Ther.35(2), 243–253 (2018).
  • BabenkoAY , SavitskayaDA , KononovaYAet al.Predictors of effectiveness of glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes and obesity. J. Diabetes Res.2, 1–12 (2019).
  • BlevinsT , PullmanJ , MalloyJet al.DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. J. Clin. Endocrinol. Metab.96(5), 1301–1310 (2011).
  • JonesAG , McDonaldTJ , ShieldsBMet al.Markers of β-cell failure predict poor glycemic response to GLP-1 receptor agonist therapy in type 2 diabetes. Diabetes Care39(2), 250–257 (2016).
  • RyderR , ThongK. GLP-1 receptor agonists in type 2 diabetes – nice guidelines versus clinical practice 2014. Br. J. Diabetes Vasc. Dis.14(2), 52–59 (2014).
  • van BloemendaalL , VeltmanDJ , ten KulveJSet al.Emotional eating is associated with increased brain responses to food-cues and reduced sensitivity to GLP-1 receptor activation. Obesity23(10), 2075–2082 (2015).
  • de BoerSA , LefrandtJD , PetersenJFet al.The effects of GLP-1 analogues in obese, insulin-using type 2 diabetes in relation to eating behaviour. Int. J. Clin. Pharm.38(1), 144–151 (2016).
  • ZhaoSh , KusminskiCM , ElmquistJK , SchererPE. Leptin: less is more. Diabetes69, 823–829 (2020).
  • Yamaoka-TojoM , TojoT , TakahiraNet al.Elevated circulating levels of an incretin hormone, glucagon-like peptide-1, are associated with metabolic components in high-risk patients with cardiovascular disease. Cardiovasc. Diabetol.9, 17 (2010).
  • LiSh , LiX. Leptin in normal physiology and leptin resistance. Sci. Bull.61(19), 1480–1488 (2015).
  • NathanBM , RudserKD , AbuzzahabMJet al.Predictors of weight-loss response with glucagon-like peptide-1 receptor agonist treatment among adolescents with severe obesity. Clin. Obes.6(1), 73–78 (2016).
  • ToyodaM , YokoyamaH , AbeKet al.Predictors of response to liraglutide in Japanese type 2 diabetes. Diabetes Res. Clin. Pract.106(3), 451–457 (2014).

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.